Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Novo Nordisk Announces Major Share Buyback Program
Novo Nordisk (NVO) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% ...
Is Novo Nordisk Stock a Buy?
Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...
Bloomberg L.P.7d
Novo Nordisk Foundation Targets US, Europe After Obesity Boost
The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Richard Parkes upgraded Novo Nordisk (NVO) to Outperform from Neutral with a DKK 930 price target The firm believes ...
Novo Nordisk: A Great Bet Amid a Global Healthcare Transformation?
Novo Nordisk (NYSE: NVO ), the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. However, the Danish pharmaceutical began because of more ...
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
moneycontrol.com1h
Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms: Report
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its ...
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...